8-K: Bicycle Therapeutics Announces Promising Imaging Data for MT1-MMP Cancer Target

Bicycle Therapeutics reports additional human imaging data validating MT1-MMP as a novel cancer target and highlighting the potential of Bicycle Radioconjugates for radiopharmaceutical imaging.

Summary

• Bicycle Therapeutics announced new human imaging data supporting MT1-MMP as a cancer target.
• The data also demonstrates the potential of Bicycle Radioconjugates (BRC) for radiopharmaceutical imaging.
• The data comes from 12 patients with various solid tumors imaged with an early BRC molecule targeting MT1-MMP.
• Initial human imaging data for a second BRC molecule targeting EphA2 is expected in the second half of 2025.
• Company-sponsored radiopharmaceutical clinical trials are planned for 2026.
• The German Cancer Consortium (DKTK) presented human imaging data conducted with an early BRC molecule targeting MT1-MMP.
• Imaging was performed in patients with advanced pulmonary adenocarcinoma, invasive ductal breast cancer, and high-grade urothelial (bladder) cancer.
• The MT1-MMP-PET scan demonstrated BRC tracer uptake in the primary tumor in the lung and in the lymph nodes and bones where the cancer had spread, corroborating the findings of the FDG-PET scan.
• MT1-MMP-PET BRC tracer uptake was comparable in lymph node metastases (SUVmax 4.7 g/mL vs. 4.4 g/mL) and higher in bone metastases (SUVmax 7.9 g/mL vs. 6.0 g/mL).
• The MT1-MMP-PET scan revealed higher BRC tracer uptake in the primary tumors in the breast (SUVmax 4.5 g/mL) and the bladder (SUVmax 6.6 g/mL) compared to contrast-enhanced CT imaging.
• The MT1-MMP-PET scan also showed the cancer spread to the lymph nodes, lower spine (sacral bone) and skull, and detected a mass in the adrenal gland above the left kidney.
• Surgery confirmed the patient had bladder cancer that spread to the lymph nodes, and immunohistochemistry (IHC) testing confirmed MT1-MMP expression in the tumor cells.
• Overall, the results demonstrate the rapid distribution of the BRC tracer throughout the body, high uptake of the BRC tracer in the primary tumor(s) and/or in metastases where the cancer spread in the body, and elimination through the kidneys.

Sentiment

Score: 8

Explanation: The announcement highlights positive imaging data and future clinical trial plans, indicating a favorable outlook for Bicycle Therapeutics' radiopharmaceutical program. The sentiment is strong due to the validation of their technology and potential for future growth.

Positives

• The data validates MT1-MMP as a promising target for cancer treatment.
• Bicycle Radioconjugates (BRC) show potential for radiopharmaceutical imaging.
• The BRC tracer demonstrates rapid distribution throughout the body and high uptake in tumors and metastases.
• The company is advancing its radiopharmaceuticals pipeline with clinical trials planned for 2026.
• The MT1-MMP-PET scan revealed higher BRC tracer uptake in the primary tumors in the breast (SUVmax 4.5 g/mL) and the bladder (SUVmax 6.6 g/mL) compared to contrast-enhanced CT imaging.

Negatives

• Imaging was unsuccessful or inconclusive in two out of 14 patients.
• In a patient with advanced pulmonary adenocarcinoma, MT1-MMP-PET imaging demonstrated lower BRC tracer uptake in the primary tumor compared to FDG-PET imaging (SUVmax 6.0 g/mL vs. 10.3 g/mL).

Risks

• The success of clinical trials is uncertain.
• Preclinical and early clinical trial results may not be predictive of future clinical trial results.
• Partnerships may not yield the intended benefits.
• The company may not achieve its radiopharmaceutical clinical development strategy.

Future Outlook

Bicycle Therapeutics anticipates sharing additional updates on its radiopharmaceuticals pipeline, including initial human imaging data for its second target EphA2 later in 2025 and the start of company-sponsored clinical radiopharmaceutical trials in 2026.

Management Comments

• Michael Skynner, Ph.D., chief technology officer of Bicycle Therapeutics, stated that the data validates MT1-MMP as a novel cancer target and positions their technology for use as potential radiopharmaceutical therapies.
• He also noted that the new imaging data builds on previous findings and is encouraged by the results seen in 12 patients with various solid tumors.

Industry Context

This announcement positions Bicycle Therapeutics in the growing radiopharmaceutical market, where targeted therapies are gaining traction for cancer treatment and imaging. Competitors in this space include companies developing radioligand therapies and imaging agents targeting various cancer-specific markers.

Comparison to Industry Standards

• The SUVmax values reported for MT1-MMP-PET imaging are within the range of other PET imaging agents used in oncology.
• For example, the SUVmax values for FDG-PET imaging in lung cancer are often in the range of 5-15 g/mL, which is comparable to the values reported in this study.
• Companies like Novartis and Telix Pharmaceuticals are also developing radioligand therapies and imaging agents for various cancer targets, and the results from Bicycle Therapeutics are competitive with these efforts.

Stakeholder Impact

• Shareholders may react positively to the promising imaging data and future clinical trial plans.
• Employees may be motivated by the progress in the radiopharmaceutical program.
• Patients may benefit from the development of new cancer imaging and treatment options.

Next Steps

• The company plans to share additional updates on its radiopharmaceuticals pipeline.
• Initial human imaging data for EphA2 is expected in the second half of 2025.
• Company-sponsored radiopharmaceutical clinical trials are planned for 2026.

Key Dates

Keywords

Bicycle Therapeutics, MT1-MMP, Radioconjugates, BRC, Cancer, Imaging, Radiopharmaceutical, EphA2, Clinical Trials